Coprescribing Naloxone to Opioid Users Helps Reduce ER Visits

Share this content:
Coprescribing Naloxone to Opioid Users Helps Reduce ER Visits
Coprescribing Naloxone to Opioid Users Helps Reduce ER Visits

TUESDAY, June 28, 2016 (HealthDay News) -- Patients on long-term opioid therapy who receive prescriptions for naloxone are less likely to return for emergency care related to opioid use, according to a study published online June 28 in the Annals of Internal Medicine.

Phillip Coffin, M.D., of Substance Use Research with the San Francisco Department of Public Health, and colleagues tracked outcomes after 38.2 percent of 1,985 patients on opioids for chronic pain at San Francisco clinics received prescriptions for naloxone.

The researchers found that those who received naloxone prescriptions had 47 percent fewer opioid-related emergency department visits per month over the following six months, and 63 percent fewer over a year, compared to opioid patients who didn't receive naloxone. However, only about 12 percent of all patients went to the emergency department for opioid-related issues during the study period. Overall, the findings suggested that naloxone prescriptions for 30 patients would translate to one averted emergency department visit, Coffin told HealthDay.

"The [U.S.] Centers for Disease Control and Prevention now recommends offering naloxone to patients on long-term opioid therapy who are taking more than 50 morphine-equivalent milligrams daily, who have a history of overdose or substance-use disorder, or who are also taking medications such as benzodiazepines," Coffin said. "Even for patients who are unlikely to overdose, it may be important to have naloxone in the house in case of accidental exposures or unintentional diversion of medications."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »